These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30179319)

  • 21. [Bullous pemphigoid: a review].
    Bernard P; Charneux J
    Ann Dermatol Venereol; 2011 Mar; 138(3):173-81. PubMed ID: 21397147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of rituximab in a case of refractory bullous pemphigoid].
    Reguiaï Z; Tchen T; Perceau G; Bernard P
    Ann Dermatol Venereol; 2009 May; 136(5):431-4. PubMed ID: 19442800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption.
    Shimanovich I; Herzog S; Schmidt E; Opitz A; Klinker E; Bröcker EB; Goebeler M; Zillikens D
    Clin Exp Dermatol; 2006 Nov; 31(6):768-74. PubMed ID: 16824051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case of bullous pemphigoid coexisting with anti-desmoglein autoantibodies.
    Tie D; Yoshida T; Chinuki Y; Da X; Ishikawa N; Morita E
    J Dermatol; 2017 Jul; 44(7):822-825. PubMed ID: 28342216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
    Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
    Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
    Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
    JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-p200 pemphigoid in a 17-year-old girl successfully treated with systemic corticosteroid and dapsone.
    Yamane N; Sawamura D; Nishie W; Abe M; Kodama K; Adachi K; Nakamura H; Ishii N; Hashimoto T; Shimizu H
    Br J Dermatol; 2007 May; 156(5):1075-8. PubMed ID: 17381449
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of bullous pemphigoid.
    Fontaine J; Joly P; Roujeau JC
    J Dermatol; 2003 Feb; 30(2):83-90. PubMed ID: 12692373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody.
    Clapé A; Muller C; Gatouillat G; Le Jan S; Barbe C; Pham BN; Antonicelli F; Bernard P
    Front Immunol; 2018; 9():479. PubMed ID: 29662486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoglobulin A antibodies against desmoglein 1, envoplakin, periplakin and BP230 in a patient with atypical bullous pemphigoid.
    Yamaki F; Mayuzumi N; Ikeda S; Hashimoto T
    J Dermatol; 2010 Mar; 37(3):255-8. PubMed ID: 20507390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human amnion membrane as a substrate for the detection of autoantibodies in pemphigus vulgaris and bullous pemphigoid.
    Sezin T; Avitan-Hersh E; Indelman M; Moscona R; Sabo E; Katz R; Pollack S; Bergman R
    Isr Med Assoc J; 2014 Apr; 16(4):217-23. PubMed ID: 24834757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study.
    Bernard P; Reguiai Z; Tancrède-Bohin E; Cordel N; Plantin P; Pauwels C; Vaillant L; Grange F; Richard-Lallemand MA; Sassolas B; Roujeau JC; Lok C; Picard-Dahan C; Chosidow O; Vitry F; Joly P
    Arch Dermatol; 2009 May; 145(5):537-42. PubMed ID: 19451497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of bullous pemphigoid with topical clobetasol propionate.
    Westerhof W
    J Am Acad Dermatol; 1989 Mar; 20(3):458-61. PubMed ID: 2645323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.
    Zhou T; Peng B; Geng S
    Front Immunol; 2021; 12():718073. PubMed ID: 34504496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of interferon-gamma in patients with refractory bullous pemphigoid.
    Nakama T; Ishii N; Ono F; Hamada T; Yasumoto S; Hashimoto T
    J Dermatol; 2007 Nov; 34(11):737-45. PubMed ID: 17973812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption.
    Westermann L; Hügel R; Meier M; Weichenthal M; Zillikens D; Gläser R; Schmidt E
    J Dermatol; 2012 Feb; 39(2):168-71. PubMed ID: 22379622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Autoimmune bullous skin diseases].
    Joly P
    Rev Med Interne; 1999 Jan; 20(1):26-38. PubMed ID: 10220817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of BP180NC16a-enzyme-linked immunosorbent assay (ELISA) in the diagnosis of bullous pemphigoid in China.
    Feng S; Lin L; Jin P; Wu Q; Zhou W; Sang H; Shao C
    Int J Dermatol; 2008 Jan; 47(1):24-8. PubMed ID: 18173596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris.
    Asashima N; Fujimoto M; Watanabe R; Nakashima H; Yazawa N; Okochi H; Tamaki K
    Br J Dermatol; 2006 Aug; 155(2):330-6. PubMed ID: 16882171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tetracycline, nicotinamide, and lesionally administered clobetasol as a therapeutic option to prednisone in patients with bullous pemphigoid: a comparative, retrospective analysis of 106 patients with long-term follow-up.
    Kalinska-Bienias A; Kowalczyk E; Jagielski P; Kowalewski C; Wozniak K
    Int J Dermatol; 2019 Feb; 58(2):172-177. PubMed ID: 30350359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.